Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carroll

Showing results (541-550 of 26,015) with videos related to

Pageof 2,602
Sort By:
Biotechnology Healthcare|February 9, 2013
Will combinatorial chemistry keep its promise?John Carroll
Biotechnology Healthcare|February 9, 2013
FDA guidances on trial endpoints could change drug developmentJohn Carroll
Biotechnology Healthcare|February 2, 2013
To States unafraid of stem cell controversy, research looks like economic stuff of lifeJohn Carroll
Biotechnology Healthcare|April 6, 2012
Everyone wants in, but with no ground rules, the biosimilar business remains elusiveJohn Carroll
Biotechnology Healthcare|January 16, 2013
Budgetary battles burden trial fundingJohn Carroll
Managed Care (Langhorne, Pa.)|May 18, 2012
Clarifying benefit packages takes time, insurers insistJohn Carroll
Managed Care (Langhorne, Pa.)|September 17, 2014
Fearful after enactment of ACA, brokers find new opportunitiesJohn Carroll
Managed Care (Langhorne, Pa.)|October 30, 2013
Europe offers example for approving biosimilarsJohn Carroll
Paediatric Respiratory Reviews|August 7, 2013
Limitations of asthma control questionnaires in the management and follow up of childhood asthmaWill Carroll
Managed Care (Langhorne, Pa.)|December 19, 2013
No informed consumers without price transparencyJohn Carroll
Pageof 2,602

Showing results (541-550 of 26,015) with videos related to

Sort By:
Pageof 2,602
Biotechnology Healthcare|February 9, 2013
Will combinatorial chemistry keep its promise?John Carroll
Biotechnology Healthcare|February 9, 2013
FDA guidances on trial endpoints could change drug developmentJohn Carroll
Biotechnology Healthcare|February 2, 2013
To States unafraid of stem cell controversy, research looks like economic stuff of lifeJohn Carroll
Biotechnology Healthcare|April 6, 2012
Everyone wants in, but with no ground rules, the biosimilar business remains elusiveJohn Carroll
Biotechnology Healthcare|January 16, 2013
Budgetary battles burden trial fundingJohn Carroll
Managed Care (Langhorne, Pa.)|May 18, 2012
Clarifying benefit packages takes time, insurers insistJohn Carroll
Managed Care (Langhorne, Pa.)|September 17, 2014
Fearful after enactment of ACA, brokers find new opportunitiesJohn Carroll
Managed Care (Langhorne, Pa.)|October 30, 2013
Europe offers example for approving biosimilarsJohn Carroll
Paediatric Respiratory Reviews|August 7, 2013
Limitations of asthma control questionnaires in the management and follow up of childhood asthmaWill Carroll
Managed Care (Langhorne, Pa.)|December 19, 2013
No informed consumers without price transparencyJohn Carroll
Pageof 2,602